All In Biotech

Drug Trial Radar · NCT06799559

Study on the Efficacy and Safety of QLM1016 in Schizophrenia

A Multicenter, Randomized, Double-blind, Parallel Controlled Study on the Efficacy and Safety of QLM1016 in the Treatment of Schizophrenia

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

402

Planned (sponsor's estimate)

Start

Oct 2, 2025

Primary completion

Oct 23, 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • 3-6mg QLM1016Drug

    3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks

  • 10-20 mg Aripiprazole oral solution filmDrug

    10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change from baseline to week 6 in the Positive and Negative Syndrome Scale (PANSS) total scoreTime frame: Time Frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • No. 8888 Lvyou Road

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.